Background: Inter-rater reliability is critical in oncology to ensure consistent and reliable measurements across raters and methods, such as when evaluating biomarker levels in different laboratories or comparing tumor size assessments by radiation oncologists during therapy planning. This consistency is essential for informed decision-making in both clinical and research contexts, and the intraclass correlation coefficient (ICC) is a widely recommended statistic for assessing agreement. This work focuses on hypothesis testing of the ICC(2,1) with two raters. Methods: We evaluated the performance of a naive permutation test for testing the hypothesis and found that it fails to reliably control the type I error rate. To address this, we developed a robust permutation test based on a studentized statistic, which we prove to be asymptotically valid even when paired variables are uncorrelated but dependent. Results: Simulation studies demonstrate that the proposed test consistently maintains type I error control, even with small sample sizes, outperforming the naive approach across various data-generating scenarios. Conclusions: The proposed studentized permutation test for ICC(2,1) offers a statistically valid and robust method for assessing inter-rater reliability and demonstrates practical utility when applied to two real-world oncology datasets.
23 January 2026 in Surgical Neurology International
Background: Meningiomas are the most common intracranial tumor. Ionizing radiation has been implicated in the pathogenesis of radiation-induced meningiomas (RIM). Compared to spontaneous meningiomas, RIM are a clinically aggressive entity and are more likely to develop clinical and radiologic progression. Methods: Systematic searches of Medline, Embase, and Cochrane Central Register of Controlled Trials were performed. Pooled data were used to calculate rates of survival, tumor control, and adverse events. Results: Thirty studies met the final inclusion criterion within this meta-analysis. In total, these studies reported on 927 RIMs in 825 patients. Patients were grouped by whether they received cranial radiotherapy ([CRT]; n = 555 patients) or scalp radiotherapy for tinea capitis ([TC]; n = 270 patients). The median dose prescribed to the CRT and TC groups was ~30 Gy and 1.5 Gy, respectively. The radiation interval to meningioma development between CRT and TC groups were 21.54 and 40.49 years, respectively ( P < 0.0001). Twenty-six studies reported a 1-year overall survival rate, with a pooled survival rate of 95.46% (95% confidence interval [CI]: 92.31–97.82%, I2 = 51.9%, P = 0.0012). One-year progression-free survival was reported by 9 studies, with a pooled rate of 99.71% (95% CI: 97.62–100.00%, I 2 = 3.3%, P = 0.4076). From two studies, the pooled 1-year local recurrence rate was 16.54% (95% CI: 0.00–34.06%, I 2 = 0.0%, P = 0.5918), while the overall pooled local recurrence rate was 27.35% (95% CI: 17.98–36.73%, I 2 = 74.5%, P < 0.0001) from 23 studies. Conclusion: High- and low-dose cranial radiation therapy can differentially influence the latency and grade of RIM, with higher dose CRT associated with earlier onset and more atypical tumors RIM screening may be warranted in individuals with an early exposure to cranial radiation given the increased risk of developing secondary neoplasms. These findings support structured long-term magnetic resonance imaging surveillance for survivors of childhood cranial irradiation, with risk adapted follow-up protocols to enable earlier detection and management.
Background: Brain metastases from renal cell carcinoma (RCC) are uncommon but clinically consequential. We evaluated survival, intracranial failure, lesion-level local failure, and MRI volumetric response after Gamma Knife radiosurgery (GKRS), including associations with systemic therapy exposure. Methods: We retrospectively identified patients treated with GKRS for intracranial RCC metastases (2001–2025). Systemic therapy exposure (TKI and/or immunotherapy) was captured time-agnostically. Overall survival (OS) and patient-level intracranial treatment failure were analyzed using Kaplan–Meier/Cox models. Lesion-level treatment failure was analyzed using clustered generalized estimating equations (GEE). Six-month volumetric response was assessed using an epsilon-stabilized log volume ratio ln{(V 6m +ϵ)/(V GKRS +ϵ)}, ε = 0.01. Results: Thirty-four patients (87 lesions) were treated; 22 deaths occurred. Overall survival was numerically longer among patients who received systemic therapy compared with those who did not, although this did not reach statistical significance (log-rank p = 0.058). In a parsimonious adjusted Cox model, TKI exposure was associated with improved OS (aHR 0.191; 95% CI 0.062–0.593; p = 0.004), as was higher KPS (HR 0.37 per 10-point increase; 95% CI 0.21–0.63; p < 0.001). Ten patient-level intracranial treatment failure events occurred, without significant differences by systemic therapy exposure. At the lesion level, 15/87 lesions failed; postoperative cavities had higher failure than intact lesions (71.4% vs. 12.5%; p = 0.001) and remained associated with failure after clustered adjustment (OR 9.92; 95% CI 1.44–68.27; p = 0.020). Dmax was not correlated with 6-month log volume ratio (ρ=−0.075; p = 0.535), but poorer 6-month volumetric response was associated with subsequent lesion failure ( p = 0.0023; clustered OR 2.84; 95% CI 1.16–6.96; p = 0.023). Conclusions: In RCC brain metastases treated with GKRS, postoperative cavities showed a higher observed rate of local failure than intact lesions, although this finding should be interpreted cautiously given the small number of cavity targets. While Dmax was not associated with early volumetric change, early 6-month volumetric trajectory was associated with subsequent local failure, suggesting a pragmatic imaging marker for risk-adapted surveillance and salvage planning. Systemic therapy exposure, particularly TKIs, was associated with OS in adjusted analysis, whereas intracranial treatment failure did not differ by systemic exposure in this cohort.
BACKGROUND AND OBJECTIVES: To study the impact of early initiation of radiation therapy (RT) in elderly patients with newly diagnosed glioblastoma. METHODS: A total of 56 elderly patients (aged 65 and older) diagnosed with isocitrate dehydrogenase (IDH)-wildtype glioblastoma were analyzed from a prospective registry from 2020 to 2024. Survival analysis was conducted to evaluate the impact of timing of RT initiation after surgical resection on survival outcomes. A specific cutoff point for RT initiation was evaluated using the log-rank test, with P -values adjustment for multiple comparisons using the false discovery rate approach. Kaplan-Meier curves were used to illustrate survival distributions. Associations of various risk factors with survival were initially examined through univariate Cox regression models, followed by multivariate analysis to assess the combined effects of these factors. The results were reported as hazard ratios with 95% CIs. RESULTS: Elderly patients with glioblastoma who underwent initiation of RT < 20 days from date of surgery demonstrated improved overall survival (OS) ( P = .0460) and progression-free survival (PFS) ( P = .0075) in our cohort. Multivariate analysis demonstrated that adjuvant temozolomide significantly affected both OS ( P = .0038) and PFS ( P = .0133). Conventionally fractionated RT consisting of 60 Gy in 30 fractions demonstrated significantly improved PFS ( P = .0164) in patients who underwent early initiation of RT (<20 days). By contrast, hypofractionated RT delivering 40 Gy in 15 fractions did not show significantly improved PFS ( P = .0509) in patients who underwent early initiation of RT (<20 days). CONCLUSION: Early initiation of RT in elderly patients with newly diagnosed glioblastoma improves both OS and progression-free survival. Timing of RT is particularly of significance in this patient population who may not be optimal candidates for systemic chemotherapy.